Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.75 GBX | -4.55% | -8.70% | -31.52% |
May. 22 | AIM WINNERS & LOSERS: Zenova scores NHS deal; Staffline "encouraged" | AN |
Apr. 02 | Belluscura sees financial hit from delay to closing TMT acquisition | AN |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 172.5 | 97.46 | 33.13 | 33.13 | - |
Enterprise Value (EV) 1 | 172.5 | 95.42 | 32.83 | 32.53 | 31.53 |
P/E ratio | -27.5 x | -11.7 x | -2.61 x | -7.44 x | 11.5 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 63.2 x | 17.9 x | 1.79 x | 0.93 x |
EV / Revenue | - | 61.8 x | 17.7 x | 1.76 x | 0.89 x |
EV / EBITDA | - | -15.4 x | -4.79 x | -16.7 x | 5.53 x |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 113,835 | 123,017 | 165,033 | 165,033 | - |
Reference price 2 | 1.515 | 0.7922 | 0.2008 | 0.2008 | 0.2008 |
Announcement Date | 2/22/22 | 6/29/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | 1.543 | 1.85 | 18.5 | 35.5 |
EBITDA 1 | - | -6.201 | -6.85 | -1.95 | 5.7 |
EBIT 1 | - | -8.129 | -9.75 | -3.8 | 2.95 |
Operating Margin | - | -526.84% | -527.03% | -20.54% | 8.31% |
Earnings before Tax (EBT) 1 | - | -8.153 | -11.6 | -4.35 | 2.4 |
Net income 1 | -5.213 | -8.153 | -11.6 | -4.35 | 2.35 |
Net margin | - | -528.4% | -627.03% | -23.51% | 6.62% |
EPS 2 | -0.0550 | -0.0680 | -0.0770 | -0.0270 | 0.0175 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 2/22/22 | 6/29/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
---|---|---|---|---|---|---|
Net sales 1 | - | 2.3 | 8.4 | 12.1 | 16.8 | 24.1 |
EBITDA 1 | - | -3.6 | -3.2 | 0.8 | 0.5 | 6.9 |
EBIT 1 | - | -4.5 | -4 | -0.1 | -1.3 | 5.1 |
Operating Margin | - | -195.65% | -47.62% | -0.83% | -7.74% | 21.16% |
Earnings before Tax (EBT) 1 | - | -4.5 | -4.1 | -0.1 | -1.3 | 5.1 |
Net income 1 | -6.419 | -4.5 | -4.1 | -0.1 | -1.3 | 5.1 |
Net margin | - | -195.65% | -48.81% | -0.83% | -7.74% | 21.16% |
EPS 2 | -0.0520 | -0.0300 | -0.0300 | - | -0.0100 | 0.0300 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 9/13/23 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - |
Net Cash position 1 | - | 2.04 | 0.3 | 0.6 | 1.6 |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 5 | 3.3 | 3 | 2 |
Capex / Sales | - | 324.16% | 178.38% | 16.22% | 5.63% |
Announcement Date | 2/22/22 | 6/29/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.52% | 33.13M | |
-5.56% | 181B | |
-0.11% | 108B | |
-6.17% | 66.12B | |
+2.64% | 50.65B | |
+6.58% | 43.11B | |
+4.91% | 41.3B | |
+21.98% | 31.6B | |
+14.45% | 25.03B | |
-5.81% | 24.16B |
- Stock Market
- Equities
- BELL Stock
- Financials Belluscura plc